The anti-obesity pill coming soon in Europe.

The anti-obesity pill coming soon in Europe.

Recommended by the EMA, it is available only for adults and on prescription and has to be associated with a reduced-calorie diet and physical activity. Mysimba is a tablet and is based on two susbances: naltrexone, normally used in treating depression and tabagism and naltrexone, usually used against drugs and alcohol dependence. However, despite good results obtained in pivotal experiments, physicians recommend to monitor patients who use Mysimba for 16 weeks.

If they don’t lose at least 5% of their initial weight, the treatment must be stopped.

Feature from the press release (click here to dowlonad) :

“The European Medicines Agency (EMA) has recommended granting a marketing authorisation for
Mysimba (naltrexone / bupropion) for weight management of overweight or obese adults. The
medicine is recommended for use in addition to a reduced-calorie diet and physical activity.
The medicine, which will only be available on prescription, provides a treatment option for adults with a
body mass index (BMI) of 30 kg/m2 or greater (obese), or a BMI of 27 kg/m2 to <30 kg/m2
(overweight) in the presence of one or more complications related to their weight, such as type 2
diabetes, high cholesterol or high blood pressure.

The place where mysimba is produced
A labor in France, where mysimba is produced

Being overweight or obese is a major risk factor for a number of chronic diseases, including diabetes
and cardiovascular disease. Currently, pharmacological therapies for weight management are limited.
Mysimba is a prolonged release tablet to be taken orally. It is a combination of two active substances
(bupropion and naltrexone) already approved for use in the European Union (EU) in other indications.
These active substances affect two key areas of the brain responsible for the control of food intake and
energy expenditure, and for the reward pathways associated with eating food.
The effectiveness of Mysimba was assessed in four pivotal studies that included obese and overweight
patients with and without weight-related conditions treated for one year. All patients enrolled in trials
were required to change their lifestyle to incorporate a reduced-calorie diet and regular physical
activity. Across these studies, more patients treated with Mysimba achieved clinically-relevant weight
loss than patients treated with placebo.
The main safety and tolerability concerns identified with Mysimba were related to central nervous
system and gastrointestinal adverse events, and uncertainties with regard to cardiovascular outcomes
in the longer term. Interim results from an ongoing cardiovascular outcome trial were reassuring in
terms of risk of serious cardiovascular disease related to treatment with Mysimba. A second study is
planned in order to continue monitoring longer-term cardiovascular safety with the medicine.

The CHMP recommended that patients started on Mysimba should be evaluated after 16 weeks. If a
patient has not lost at least five per cent of their initial body weight by this time, treatment with
Mysimba should be stopped. The product information for this medicine provides advice on the safe use
of the product.
The opinion adopted by the CHMP at its December 2014 meeting is an intermediary step on Mysimba’s
path to patient access. The CHMP opinion will now be sent to the European Commission for the
adoption of a decision on an EU-wide marketing authorisation. Once a marketing authorisation has
been granted, decisions about price and reimbursement will then take place at the level of each
Member State considering the potential use of Mysimba in the context of the national health system of
that country” 

source: European Medicines Agency


Our Facebook page Comments


We are proud to announce that MEDLINES – Healthcare headlines started its’ very own blog site. Our mission is to bring the very best of the news and newsworthy issues of the medical field, from university news to business and tech info.